Evidence map›Paper›PMID 29587864›Full record

ArticleTrials2018

Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol.

Ayano Kelly, Allison Tong, Kathleen Tymms, Lyn March, Jonathan C Craig, Mary De Vera, Vicki Evans, Geraldine Hassett, Karine Toupin-April, Bart van den Bemt and 19 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Risk of bias tools for medication adherence research: RoBIAS and RoBOAS.British journal of clinical pharmacology · 2025
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 16 institutions in 7 countries.

Ayano KellyCanberra Rheumatology, Level 9, 40 Marcus Clarke St, Canberra City, ACT, 2606, Australia. ayano.kelly@anu.edu.au.ORCID http://orcid.org/0000-0003-3325-3840
Allison TongCentre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Kathleen TymmsCanberra Rheumatology, Level 9, 40 Marcus Clarke St, Canberra City, ACT, 2606, Australia.
Lyn MarchDepartment of Rheumatology, Royal North Shore Hospital, Sydney, NSW, Australia.
Jonathan C CraigCentre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Mary De VeraFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.
Vicki EvansPatient Research Partner, Clear Vision Consulting, Canberra, ACT, Australia.
Geraldine HassettDepartment of Rheumatology, Liverpool Hospital, Sydney, NSW, Australia.
Karine Toupin-AprilChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
Bart van den BemtDepartment of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands.
Armando Teixeira-PintoCentre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Rieke AltenDepartment of Rheumatology, Clinical Immunology, Osteology, Physical therapy and Sports Medicine, Schlosspark Klinik, Charité University Medicine, Berlin, Germany.
Susan J BartlettDepartment of Medicine, McGill University, Montreal, Canada.
Willemina CampbellPatient Research Partner, Toronto Western Hospital, Toronto, Ottawa, Canada.
Therese DawsonLord Street Specialist Centre, Port Macquarie, NSW, Australia.
Michael GillPatient Research Partner, Dragon Claw, Sydney, NSW, Australia.
Renske HebingAmsterdam Rheumatology and Immunology Centre, Amsterdam, Netherlands.
Alexa MearaThe Ohio State University, Wexner Medical Center, Columbus, OH, USA.
Robby NieuwlaatDepartment of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
Yomei ShawNational Data Bank for Rheumatic Diseases, Wichita, KS, USA.
Jasvinder A SinghMedicine Service, VA Medical Center, Birmingham, AL, USA.
Maria Suarez-AlmazorSection of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daniel SumptonCentre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Peter WongMid-North Coast Arthritis Clinic, Coffs Harbour, NSW, Australia.
Robin ChristensenMusculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
Dorcas BeatonMusculoskeletal Health & Outcomes Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.
Maarten de WitMetamedica, VU Medical Centre, Amsterdam, The Netherlands.
Peter TugwellDepartment of Medicine, University of Ottawa, Ottawa, ON, Canada.
OMERACT-Adherence Group
The University of Sydney · AUAustralian National University · AUUniversity of Ottawa · CAJohns Hopkins University · USSt. Michael's Hospital · CAThe Ohio State University Wexner Medical Center · USCanberra Hospital · AUFrederiksberg Hospital · DKLiverpool Hospital · AUMayo Hospital · THRadboud University Nijmegen · NLThe National Databank for Rheumatic Diseases · USThe University of Texas MD Anderson Cancer Center · USToronto Western Hospital · CAUniversity of Alabama at Birmingham · USUniversity of British Columbia · CA

Funding

Arthritis Australia 2018 Arthritis Australia GrantStephen Hall N/A
6 · The paper itself

Abstract

backgroundOver the last 20 years, there have been marked improvements in the availability of effective medications for rheumatic conditions such as gout, osteoporosis and rheumatoid arthritis (RA), which have led to a reduction in disease flares and the risk of re-fracture in osteoporosis, and the slowing of disease progression in RA. However, medication adherence remains suboptimal, as treatment regimens can be complex and difficult to continue long term. Many trials have been conducted to improve adherence to medication. Core domains, which are the outcomes of most relevance to patients and clinicians, are a pivotal component of any trial. These core domains should be measured consistently, so that all relevant trials can be combined in systematic reviews and meta-analyses to reach conclusions that are more valid. Failure to do this severely limits the potential for trial-based evidence to inform decisions on how to support medication adherence. The Outcome Measures in Rheumatology (OMERACT) - Interventions for Medication Adherence study by the OMERACT-Adherence Group aims to develop a core domain set for interventions that aim to support medication adherence in rheumatology. METHODS/

designThis OMERACT-Adherence study has five phases: (1) a systematic review to identify outcome domains that have been reported in interventions focused on supporting medication adherence in rheumatology; (2) semi-structured stakeholder interviews with patients and caregivers to determine their views on the core domains; (3) focus groups using the nominal group technique with patients and caregivers to identify and rank domains that are relevant to them, including the reasons for their choices; (4) an international three-round modified Delphi survey involving patients with diverse rheumatic conditions, caregivers, health professionals, researchers and other stakeholders to develop a preliminary core domain set; and (5) a stakeholder workshop with OMERACT members to review, vote on and reach a consensus on the core domain set for interventions to support medication adherence in rheumatology. DISCUSSION: Establishing a core domain set to be reported in all intervention studies undertaken to support patients with medication adherence will enhance the relevance and the impact of these results and improve the lives of people with rheumatic conditions.

Indexed as

Antirheumatic AgentsClinical Trials as TopicMedication AdherenceOutcome Assessment, Health CareResearch DesignRheumatic DiseasesCaregiversConsensus Statements as TopicDelphi TechniqueHealth Knowledge, Attitudes, PracticeHumansInterviews as TopicPatientsStakeholder ParticipationSystematic Reviews as TopicTreatment OutcomeAntirheumatic AgentsAdherenceClinical trialsComplianceCore domain setMedication AdherenceOutcomes researchPatient-centred outcomesPersistenceRheumatology

Identifiers

PMID29587864
PMCPMC5870260
OpenAlexW2796053080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.